NR 546 / NR546 Midterm Exam | Latest | A+ Guarantee
NR 546 / NR546 Midterm Exam
Latest Tested Questions with Revised Answers
A+ Guarantee | 75 Verified Questions with Comprehensive Rationales
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum
Aligned with 2026-2027 PMHNP Certification Competencies
EXAMINATION OVERVIEW
Total Questions: 75 (multiple choice, single best answer)
Format: 70% scenario-based | 20% direct recall | 10% clinical analysis
Cognitive Distribution: 30% recall | 50% application | 20% analysis
Sections: (1) Neurobiology & Neurotransmission | (2) Pharmacokinetics & Pharmacodynamics | (3)
Antidepressants & Mood Stabilizers | (4) Anxiolytics, Hypnotics & Sedatives | (5) Antipsychotics & ADHD
Medications | (6) Integrated Clinical Scenarios
Instructions: Select the SINGLE best answer for each question. Each correct answer is marked [CORRECT]
and is followed by a comprehensive rationale grounded in advanced psychopharmacology, receptor
pharmacology, and evidence-based PMHNP practice.
Section 1: Neurobiology and Neurotransmission
Neuronal Structure, Synaptic Transmission, and Neurotransmitter Systems
Q1: A 24-year-old neuroscience student is studying the propagation of action potentials along a myelinated
axon. Which structural feature is primarily responsible for the rapid, saltatory conduction observed in
myelinated neurons, and what is the underlying biophysical mechanism?
A. Nodes of Ranvier, where myelin is absent and voltage-gated sodium channels are densely concentrated,
allowing depolarization to 'jump' between nodes [CORRECT]
B. The myelin sheath itself, which contains voltage-gated sodium channels that depolarize in sequence along the
entire axon length
C. Schwann cell nuclei, which generate local electrical currents that propagate the action potential through
capacitive coupling
D. The axonal microtubules, which physically transport the depolarization wave via dynein-mediated conduction
Correct Answer: A
Rationale: Saltatory conduction occurs because the myelin sheath electrically insulates internodal segments, forcing
depolarization to regenerate only at the Nodes of Ranvier, where voltage-gated Na+ channels cluster densely. This reduces
membrane capacitance and increases resistance across internodes, producing conduction velocities up to 50x faster than
unmyelinated fibers. The other options misattribute conduction to myelin itself (which lacks channels), Schwann nuclei, or
cytoskeletal transport — none of which generate or propagate electrical depolarization.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 1
,NR 546 / NR546 Midterm Exam | Latest | A+ Guarantee
Q2: A patient with schizophrenia demonstrates prominent positive symptoms (hallucinations, delusions)
that respond to D2 antagonist antipsychotics. Overactivity in which dopaminergic pathway is most directly
implicated in the pathophysiology of these positive symptoms?
A. Nigrostriatal pathway, projecting from the substantia nigra pars compacta to the dorsal striatum
B. Mesolimbic pathway, projecting from the ventral tegmental area (VTA) to the nucleus accumbens and
limbic structures [CORRECT]
C. Mesocortical pathway, projecting from the VTA to the prefrontal cortex
D. Tuberoinfundibular pathway, projecting from the arcuate nucleus of the hypothalamus to the pituitary stalk
Correct Answer: B
Rationale: The mesolimbic pathway (VTA to nucleus accumbens/limbic structures) mediates reward and incentive
motivation, and its hyperactivity is the canonical dopaminergic abnormality underlying positive psychotic symptoms. The
nigrostriatal pathway governs movement (D2 blockade there causes EPS), the mesocortical pathway governs cognition and
negative symptoms (hypoactivity, not hyperactivity), and the tuberoinfundibular pathway regulates prolactin (D2 blockade
causes hyperprolactinemia). Identifying the correct pathway is foundational for understanding both symptom genesis and
antipsychotic side-effect profiles.
Q3: A 38-year-old male treated with haloperidol develops cogwheel rigidity, bradykinesia, and a shuffling
gait. Disruption of which dopaminergic pathway best explains these extrapyramidal symptoms (EPS)?
A. Mesolimbic pathway, due to excessive dopaminergic tone in the ventral striatum
B. Mesocortical pathway, due to reduced prefrontal dopamine signaling
C. Nigrostriatal pathway, due to D2 blockade in the dorsal striatum mimicking Parkinsonian dopamine
depletion [CORRECT]
D. Tuberoinfundibular pathway, due to disinhibition of prolactin release from the anterior pituitary
Correct Answer: C
Rationale: EPS such as parkinsonism arise from D2 receptor blockade in the nigrostriatal pathway, which functionally
mimics the dopaminergic depletion of idiopathic Parkinson's disease. The mesolimbic pathway mediates positive symptoms
(its blockade is therapeutic), the mesocortical pathway governs cognition/negative symptoms, and the tuberoinfundibular
pathway controls prolactin (blockade produces galactorrhea, not movement disorders). Recognizing the nigrostriatal origin
guides EPS management with anticholinergics or dose reduction.
Q4: A 29-year-old woman on risperidone reports galactorrhea, amenorrhea, and decreased libido.
Laboratory testing reveals a markedly elevated serum prolactin level. Which dopaminergic pathway is
inhibited by the medication, leading to this endocrine disturbance?
A. Mesolimbic pathway, where D2 blockade disinhibits reward-mediated prolactin surge
B. Nigrostriatal pathway, where D2 blockade increases prolactin via the basal ganglia-pituitary axis
C. Tuberoinfundibular pathway, where D2 blockade removes tonic inhibition of prolactin release from the
anterior pituitary [CORRECT]
D. Mesocortical pathway, where D2 blockade alters prefrontal regulation of gonadotropin-releasing hormone
Correct Answer: C
Rationale: Dopamine released from the tuberoinfundibular pathway normally acts as prolactin-inhibiting factor (PIF) at D2
receptors on lactotrophs in the anterior pituitary. D2 antagonists such as risperidone remove this tonic inhibition, causing
hyperprolactinemia, galactorrhea, amenorrhea, and sexual dysfunction. The other pathways do not regulate prolactin;
misidentifying them would lead to incorrect etiologic reasoning and management.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 2
,NR 546 / NR546 Midterm Exam | Latest | A+ Guarantee
Q5: A PMHNP student is explaining the neuroanatomic origin of serotonergic projections to a peer. Which
brainstem structure serves as the primary source of serotonergic neurons projecting diffusely to the
forebrain, and which clinical functions are most directly modulated by this system?
A. The locus coeruleus, modulating arousal, alertness, and mood
B. The raphe nuclei, modulating mood, appetite, sleep, and impulse control [CORRECT]
C. The substantia nigra pars compacta, modulating motor control and reward
D. The ventral tegmental area, modulating cognition and executive function
Correct Answer: B
Rationale: The raphe nuclei, located along the midline of the brainstem, contain the vast majority of serotonergic cell bodies
that project diffusely to forebrain structures. This system regulates mood, appetite, sleep-wake cycles, and impulse control —
the same domains targeted by SSRIs. The locus coeruleus is the source of norepinephrine, the substantia nigra is
dopaminergic (motor), and the VTA is dopaminergic (reward/cognition). Confusing these nuclei is a common NR 546 error
with direct pharmacologic consequences.
Q6: A patient taking a selective norepinephrine-related medication reports increased alertness, energy,
and mild anxiety. Which neuroanatomic structure is the principal source of noradrenergic neurons that
project to the forebrain and mediate these arousal-related effects?
A. The raphe nuclei, providing diffuse serotonergic innervation to the cortex
B. The locus coeruleus, providing diffuse noradrenergic projections that regulate arousal, alertness, and
mood [CORRECT]
C. The basal nucleus of Meynert, providing cholinergic input to the cortex
D. The ventral tegmental area, providing dopaminergic input to the prefrontal cortex
Correct Answer: B
Rationale: The locus coeruleus is the brain's principal noradrenergic nucleus; its diffuse forebrain projections regulate
arousal, vigilance, alertness, and contribute to mood. Medications enhancing NE signaling (e.g., SNRIs, atomoxetine)
produce alertness and, at higher doses, anxiety. The raphe nuclei are serotonergic, the basal nucleus of Meynert is cholinergic,
and the VTA is dopaminergic — each mediating distinct functional domains.
Q7: A 45-year-old patient with generalized anxiety disorder is prescribed a medication that enhances the
activity of the primary inhibitory neurotransmitter in the CNS. Which neurotransmitter is being targeted,
and what is its principal mechanism of action at the receptor level?
A. Glutamate, opening ligand-gated Na+ channels to depolarize postsynaptic neurons
B. GABA, binding GABA-A receptors to increase Cl- influx and hyperpolarize the postsynaptic membrane
[CORRECT]
C. Acetylcholine, activating nicotinic receptors to increase cation conductance
D. Dopamine, activating D1 receptors to increase cAMP and neuronal excitability
Correct Answer: B
Rationale: GABA is the major inhibitory neurotransmitter in the CNS. Binding of GABA to GABA-A receptors opens
intrinsic chloride channels, causing Cl- influx, membrane hyperpolarization, and reduced neuronal firing — the molecular
basis of anxiolysis, sedation, and seizure prevention. Benzodiazepines are positive allosteric modulators at this receptor.
Glutamate is excitatory (not inhibitory), and the other options misidentify both the neurotransmitter and the ionic mechanism.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 3
, NR 546 / NR546 Midterm Exam | Latest | A+ Guarantee
Q8: A researcher is investigating a drug intended to enhance learning and memory by modulating the
major excitatory neurotransmitter in the CNS. Which neurotransmitter system is the most appropriate
pharmacologic target?
A. GABA, the major inhibitory neurotransmitter mediating cortical suppression
B. Glutamate, acting at NMDA, AMPA, and kainate receptors to mediate excitatory signaling, synaptic
plasticity, and long-term potentiation [CORRECT]
C. Serotonin, acting at 5-HT receptors to modulate mood and appetite
D. Glycine, acting at strychnine-sensitive receptors in the spinal cord
Correct Answer: B
Rationale: Glutamate is the major excitatory neurotransmitter in the CNS, acting at ionotropic (NMDA, AMPA, kainate) and
metabotropic receptors. NMDA receptor activation is central to long-term potentiation (LTP), the cellular correlate of
learning and memory. GABA is inhibitory, serotonin modulates mood rather than excitatory plasticity, and glycine is
primarily a spinal cord inhibitory transmitter. Modulating glutamatergic tone (e.g., ketamine's NMDA antagonism) is
increasingly relevant to depression and cognitive therapeutics.
Q9: A novel compound binds a receptor and within milliseconds produces a conformational change that
directly opens an ion channel embedded within the receptor protein itself. Which receptor classification
best describes this pharmacologic target?
A. G-protein coupled receptor (metabotropic), which activates adenylyl cyclase through a second messenger
cascade
B. Ligand-gated ion channel (ionotropic), where receptor and channel are the same protein complex
allowing rapid signaling [CORRECT]
C. Intracellular/nuclear receptor, which alters gene transcription over hours to days
D. Kinase-linked receptor, which autophosphorylates tyrosine residues to initiate a signaling cascade
Correct Answer: B
Rationale: Ligand-gated ion channels (ionotropic receptors) contain the binding site and the ion pore within the same
macromolecular complex, producing millisecond-scale signaling — exemplified by the nicotinic ACh, GABA-A, 5-HT3, and
NMDA receptors. GPCRs (metabotropic) signal via second messengers over seconds, kinase-linked receptors (e.g., growth
factor receptors) act over minutes, and nuclear receptors (e.g., glucocorticoid) alter transcription over hours. The rapid onset
is the key distinguishing feature.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 4
NR 546 / NR546 Midterm Exam
Latest Tested Questions with Revised Answers
A+ Guarantee | 75 Verified Questions with Comprehensive Rationales
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum
Aligned with 2026-2027 PMHNP Certification Competencies
EXAMINATION OVERVIEW
Total Questions: 75 (multiple choice, single best answer)
Format: 70% scenario-based | 20% direct recall | 10% clinical analysis
Cognitive Distribution: 30% recall | 50% application | 20% analysis
Sections: (1) Neurobiology & Neurotransmission | (2) Pharmacokinetics & Pharmacodynamics | (3)
Antidepressants & Mood Stabilizers | (4) Anxiolytics, Hypnotics & Sedatives | (5) Antipsychotics & ADHD
Medications | (6) Integrated Clinical Scenarios
Instructions: Select the SINGLE best answer for each question. Each correct answer is marked [CORRECT]
and is followed by a comprehensive rationale grounded in advanced psychopharmacology, receptor
pharmacology, and evidence-based PMHNP practice.
Section 1: Neurobiology and Neurotransmission
Neuronal Structure, Synaptic Transmission, and Neurotransmitter Systems
Q1: A 24-year-old neuroscience student is studying the propagation of action potentials along a myelinated
axon. Which structural feature is primarily responsible for the rapid, saltatory conduction observed in
myelinated neurons, and what is the underlying biophysical mechanism?
A. Nodes of Ranvier, where myelin is absent and voltage-gated sodium channels are densely concentrated,
allowing depolarization to 'jump' between nodes [CORRECT]
B. The myelin sheath itself, which contains voltage-gated sodium channels that depolarize in sequence along the
entire axon length
C. Schwann cell nuclei, which generate local electrical currents that propagate the action potential through
capacitive coupling
D. The axonal microtubules, which physically transport the depolarization wave via dynein-mediated conduction
Correct Answer: A
Rationale: Saltatory conduction occurs because the myelin sheath electrically insulates internodal segments, forcing
depolarization to regenerate only at the Nodes of Ranvier, where voltage-gated Na+ channels cluster densely. This reduces
membrane capacitance and increases resistance across internodes, producing conduction velocities up to 50x faster than
unmyelinated fibers. The other options misattribute conduction to myelin itself (which lacks channels), Schwann nuclei, or
cytoskeletal transport — none of which generate or propagate electrical depolarization.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 1
,NR 546 / NR546 Midterm Exam | Latest | A+ Guarantee
Q2: A patient with schizophrenia demonstrates prominent positive symptoms (hallucinations, delusions)
that respond to D2 antagonist antipsychotics. Overactivity in which dopaminergic pathway is most directly
implicated in the pathophysiology of these positive symptoms?
A. Nigrostriatal pathway, projecting from the substantia nigra pars compacta to the dorsal striatum
B. Mesolimbic pathway, projecting from the ventral tegmental area (VTA) to the nucleus accumbens and
limbic structures [CORRECT]
C. Mesocortical pathway, projecting from the VTA to the prefrontal cortex
D. Tuberoinfundibular pathway, projecting from the arcuate nucleus of the hypothalamus to the pituitary stalk
Correct Answer: B
Rationale: The mesolimbic pathway (VTA to nucleus accumbens/limbic structures) mediates reward and incentive
motivation, and its hyperactivity is the canonical dopaminergic abnormality underlying positive psychotic symptoms. The
nigrostriatal pathway governs movement (D2 blockade there causes EPS), the mesocortical pathway governs cognition and
negative symptoms (hypoactivity, not hyperactivity), and the tuberoinfundibular pathway regulates prolactin (D2 blockade
causes hyperprolactinemia). Identifying the correct pathway is foundational for understanding both symptom genesis and
antipsychotic side-effect profiles.
Q3: A 38-year-old male treated with haloperidol develops cogwheel rigidity, bradykinesia, and a shuffling
gait. Disruption of which dopaminergic pathway best explains these extrapyramidal symptoms (EPS)?
A. Mesolimbic pathway, due to excessive dopaminergic tone in the ventral striatum
B. Mesocortical pathway, due to reduced prefrontal dopamine signaling
C. Nigrostriatal pathway, due to D2 blockade in the dorsal striatum mimicking Parkinsonian dopamine
depletion [CORRECT]
D. Tuberoinfundibular pathway, due to disinhibition of prolactin release from the anterior pituitary
Correct Answer: C
Rationale: EPS such as parkinsonism arise from D2 receptor blockade in the nigrostriatal pathway, which functionally
mimics the dopaminergic depletion of idiopathic Parkinson's disease. The mesolimbic pathway mediates positive symptoms
(its blockade is therapeutic), the mesocortical pathway governs cognition/negative symptoms, and the tuberoinfundibular
pathway controls prolactin (blockade produces galactorrhea, not movement disorders). Recognizing the nigrostriatal origin
guides EPS management with anticholinergics or dose reduction.
Q4: A 29-year-old woman on risperidone reports galactorrhea, amenorrhea, and decreased libido.
Laboratory testing reveals a markedly elevated serum prolactin level. Which dopaminergic pathway is
inhibited by the medication, leading to this endocrine disturbance?
A. Mesolimbic pathway, where D2 blockade disinhibits reward-mediated prolactin surge
B. Nigrostriatal pathway, where D2 blockade increases prolactin via the basal ganglia-pituitary axis
C. Tuberoinfundibular pathway, where D2 blockade removes tonic inhibition of prolactin release from the
anterior pituitary [CORRECT]
D. Mesocortical pathway, where D2 blockade alters prefrontal regulation of gonadotropin-releasing hormone
Correct Answer: C
Rationale: Dopamine released from the tuberoinfundibular pathway normally acts as prolactin-inhibiting factor (PIF) at D2
receptors on lactotrophs in the anterior pituitary. D2 antagonists such as risperidone remove this tonic inhibition, causing
hyperprolactinemia, galactorrhea, amenorrhea, and sexual dysfunction. The other pathways do not regulate prolactin;
misidentifying them would lead to incorrect etiologic reasoning and management.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 2
,NR 546 / NR546 Midterm Exam | Latest | A+ Guarantee
Q5: A PMHNP student is explaining the neuroanatomic origin of serotonergic projections to a peer. Which
brainstem structure serves as the primary source of serotonergic neurons projecting diffusely to the
forebrain, and which clinical functions are most directly modulated by this system?
A. The locus coeruleus, modulating arousal, alertness, and mood
B. The raphe nuclei, modulating mood, appetite, sleep, and impulse control [CORRECT]
C. The substantia nigra pars compacta, modulating motor control and reward
D. The ventral tegmental area, modulating cognition and executive function
Correct Answer: B
Rationale: The raphe nuclei, located along the midline of the brainstem, contain the vast majority of serotonergic cell bodies
that project diffusely to forebrain structures. This system regulates mood, appetite, sleep-wake cycles, and impulse control —
the same domains targeted by SSRIs. The locus coeruleus is the source of norepinephrine, the substantia nigra is
dopaminergic (motor), and the VTA is dopaminergic (reward/cognition). Confusing these nuclei is a common NR 546 error
with direct pharmacologic consequences.
Q6: A patient taking a selective norepinephrine-related medication reports increased alertness, energy,
and mild anxiety. Which neuroanatomic structure is the principal source of noradrenergic neurons that
project to the forebrain and mediate these arousal-related effects?
A. The raphe nuclei, providing diffuse serotonergic innervation to the cortex
B. The locus coeruleus, providing diffuse noradrenergic projections that regulate arousal, alertness, and
mood [CORRECT]
C. The basal nucleus of Meynert, providing cholinergic input to the cortex
D. The ventral tegmental area, providing dopaminergic input to the prefrontal cortex
Correct Answer: B
Rationale: The locus coeruleus is the brain's principal noradrenergic nucleus; its diffuse forebrain projections regulate
arousal, vigilance, alertness, and contribute to mood. Medications enhancing NE signaling (e.g., SNRIs, atomoxetine)
produce alertness and, at higher doses, anxiety. The raphe nuclei are serotonergic, the basal nucleus of Meynert is cholinergic,
and the VTA is dopaminergic — each mediating distinct functional domains.
Q7: A 45-year-old patient with generalized anxiety disorder is prescribed a medication that enhances the
activity of the primary inhibitory neurotransmitter in the CNS. Which neurotransmitter is being targeted,
and what is its principal mechanism of action at the receptor level?
A. Glutamate, opening ligand-gated Na+ channels to depolarize postsynaptic neurons
B. GABA, binding GABA-A receptors to increase Cl- influx and hyperpolarize the postsynaptic membrane
[CORRECT]
C. Acetylcholine, activating nicotinic receptors to increase cation conductance
D. Dopamine, activating D1 receptors to increase cAMP and neuronal excitability
Correct Answer: B
Rationale: GABA is the major inhibitory neurotransmitter in the CNS. Binding of GABA to GABA-A receptors opens
intrinsic chloride channels, causing Cl- influx, membrane hyperpolarization, and reduced neuronal firing — the molecular
basis of anxiolysis, sedation, and seizure prevention. Benzodiazepines are positive allosteric modulators at this receptor.
Glutamate is excitatory (not inhibitory), and the other options misidentify both the neurotransmitter and the ionic mechanism.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 3
, NR 546 / NR546 Midterm Exam | Latest | A+ Guarantee
Q8: A researcher is investigating a drug intended to enhance learning and memory by modulating the
major excitatory neurotransmitter in the CNS. Which neurotransmitter system is the most appropriate
pharmacologic target?
A. GABA, the major inhibitory neurotransmitter mediating cortical suppression
B. Glutamate, acting at NMDA, AMPA, and kainate receptors to mediate excitatory signaling, synaptic
plasticity, and long-term potentiation [CORRECT]
C. Serotonin, acting at 5-HT receptors to modulate mood and appetite
D. Glycine, acting at strychnine-sensitive receptors in the spinal cord
Correct Answer: B
Rationale: Glutamate is the major excitatory neurotransmitter in the CNS, acting at ionotropic (NMDA, AMPA, kainate) and
metabotropic receptors. NMDA receptor activation is central to long-term potentiation (LTP), the cellular correlate of
learning and memory. GABA is inhibitory, serotonin modulates mood rather than excitatory plasticity, and glycine is
primarily a spinal cord inhibitory transmitter. Modulating glutamatergic tone (e.g., ketamine's NMDA antagonism) is
increasingly relevant to depression and cognitive therapeutics.
Q9: A novel compound binds a receptor and within milliseconds produces a conformational change that
directly opens an ion channel embedded within the receptor protein itself. Which receptor classification
best describes this pharmacologic target?
A. G-protein coupled receptor (metabotropic), which activates adenylyl cyclase through a second messenger
cascade
B. Ligand-gated ion channel (ionotropic), where receptor and channel are the same protein complex
allowing rapid signaling [CORRECT]
C. Intracellular/nuclear receptor, which alters gene transcription over hours to days
D. Kinase-linked receptor, which autophosphorylates tyrosine residues to initiate a signaling cascade
Correct Answer: B
Rationale: Ligand-gated ion channels (ionotropic receptors) contain the binding site and the ion pore within the same
macromolecular complex, producing millisecond-scale signaling — exemplified by the nicotinic ACh, GABA-A, 5-HT3, and
NMDA receptors. GPCRs (metabotropic) signal via second messengers over seconds, kinase-linked receptors (e.g., growth
factor receptors) act over minutes, and nuclear receptors (e.g., glucocorticoid) alter transcription over hours. The rapid onset
is the key distinguishing feature.
Chamberlain University | Advanced Psychopharmacology | PMHNP Curriculum Page 4
